logo
Fossil teeth analysis upends what's known about megalodon's diet, scientists say

Fossil teeth analysis upends what's known about megalodon's diet, scientists say

CNN27-05-2025
What scientists understand about the voracious feeding habits of the colossal megalodon could be up for some revision.
The prehistoric predator that went extinct about 3.6 million years ago was not hunting only large marine mammals such as whales as researchers widely thought, a new study has found. Instead, minerals in fossilized teeth reveal that megalodon might have been an opportunistic feeder to meet its remarkable 100,000-calorie-per-day requirement.
'When available, it would probably have fed on large prey items, but when not available, it was flexible enough to feed also on smaller animals to fulfill its dietary requirements,' said lead study author Jeremy McCormack, a geoscientist at Goethe University in Frankfurt, Germany.
The study, published Monday in the journal Earth and Planetary Science Letters, also showed there were regional differences in the giant shark's feeding habits. The finding suggests megalodon would pursue whatever was in local waters, devouring other top predators and smaller prey alike.
'They were not concentrating on certain prey types, but they must have fed throughout the food web, on many different species,' McCormack said. While certainly this was a fierce apex predator, and no one else would probably prey on an adult megalodon, it's clear that they themselves could potentially feed on almost everything else that swam around.'
Megalodon dispatched its prey with a ferocious bite and lethal, serrated teeth that could reach up to 7 inches (18 centimeters) long — the size of a human hand. The superpredator's teeth — abundant in the fossil record — are what McCormack and his colleagues used to conduct a geochemical analysis, unlocking fresh clues that could challenge megalodon's role as sole king of the ancient seas.
It's not the first time that a study has challenged previous knowledge about the enormous sea creature. In fact, many questions remain unanswered about Otodus megalodon — its scientific species name meaning 'giant tooth' — since no complete fossil has ever been discovered. The lack of hard evidence stems from the fact that fish skeletons are made of softer cartilage rather than bone, so they don't fossilize very well.
Recent research found that the animal was more warm-blooded than other sharks, for example, and there is an ongoing debate about its size and shape. Scientists who created a 3D reconstruction suggested in 2022 that megalodon was about three times as long as a great white shark — about 52 feet (16 meters). However, a March study hypothesized that the megashark was actually much larger — up to 80 feet (24 meters) in length and even longer than the fictional version in the 2018 blockbuster 'The Meg,' which suggested the ancient predator was 75 feet (23 meters) from head to tail.
As for megalodon's feeding habits, determining what it ate based on fossil evidence poses challenges, according to McCormack. 'We know that they fed on large marine mammals from tooth bite marks,' he said. 'Of course, you can see bite marks on the bones of marine mammals, but you will not see them if they fed on other sharks, because sharks don't have bones. So there's already a bias in this kind of fossil record.'
To glean more about megalodon's prey selection, McCormack and his coauthors looked at the giant shark's fossilized teeth and compared them with those of other animals that lived at the same time, as well as teeth from modern sharks and other predators such as dolphins. The researchers used specimens from museum collections and samples from beached animal carcasses.
Specifically, the study team conducted a lab analysis of zinc, a mineral that is acquired only through food.
Zinc is essential for living organisms and plays a crucial role in tooth development. The ratio of heavy and light zinc isotopes in the sharks' tooth enamel preserves a record of the kind of animal matter that they ate.
Different types, or isotopes, of zinc are absorbed when fish and other animals eat, but one of them — zinc-66 — is stored in tooth enamel much less than another, zinc-64. The ratio between those zinc isotopes widens the further away an animal gets from the lowest level of the food chain. That means that a fish eating other fish would have lower levels of zinc-66 compared with zinc-64, and the fish that eat those fish will have even less zinc-66 compared with zinc-64, creating ratio markers that can help draw up a sequence of the food chain.
The researchers found that sea bream, a fish that feeds on mussels and crustaceans, was at the bottom of their reconstructed chain, followed by smaller sharks from the Carcharhinus genus, up to 9.8 feet (3 meters) in length, and extinct toothed whales comparable in size to modern dolphins.
Farther up were larger sharks such as the Galeocerdo aduncus, similar to a modern tiger shark, and occupying the top slot was megalodon — but its zinc ratios were not so different as to suggest a massive gap with the lower-tier animals, meaning they might have been part of megalodon's diet, too. 'Based on our new results, we see that it was clear it could feed at the very top, but it was flexible enough to feed also on lower (levels of the food chain),' McCormack said.
In addition, the researchers found megalodon was not alone at the top of the food chain but instead shared the spot with other 'opportunistic supercarnivores' such as its close relative Otodus chubutensis and the lesser-known Araloselachus cuspidatus, another giant fish-eating shark.
That revelation challenges the assumption that megalodon was the exclusive ruler of the oceans and draws comparisons with the great white shark, another large opportunistic feeder. The finding also reinforces the idea that the rise of the great white may have been a factor in megalodon's extinction, according to paleobiologist Kenshu Shimada, one of the coauthors of the latest study.
'One of the contributing factors for the demise of megalodon has been hypothesized to be the rise of the great white shark, which feeds on fish when young and shifts its diet to marine mammals as it becomes larger,' said Shimada, a professor of biological and environmental sciences at DePaul University in Chicago.
'Our new study, that demonstrates the 'diet overlap' between the great white shark and megalodon, strengthens the idea that the evolution of the smaller, likely more agile and maneuverable great white shark could have indeed (driven) megalodon to extinction.'
The new research allows scientists to recreate a snapshot of the marine food web that existed about 20 million years ago, according to Jack Cooper, a UK-based paleobiologist and megalodon expert who wasn't involved with the study.
'The general picture of megalodon has been of a gigantic shark munching on whales,' Cooper said in an email. 'This study adds a new dimension that megalodon probably had a wide range of prey — essentially, it probably ate not just whales but whatever it wanted.'
Another interesting find, he added, is that megalodon's diet probably varied slightly between different populations, something observed in today's great white sharks. 'This makes sense and is something we would have probably expected since megalodon lived all over the world and not all of its prey items would have done; but it's wonderful to have concrete data supporting this hypothesis,' Cooper said.
The study adds to a growing body of evidence that is reshaping commonly held beliefs about megalodon and its close relatives, said Alberto Collareta, a researcher in the department of Earth sciences at Italy's University of Pisa who was not involved in the research.
'These have led us to abandon traditional reconstruction of the megatooth sharks as 'inflated' versions of the modern white shark. We now know that the Megalodon was something else — in terms of size, shape and ancestry, and of biology, too,' Collareta said via email.
'The Miocene (palaeo)ecosystems in question did not work in a radically different way compared to their modern counterparts — even if they feature … completely extinct protagonists such as the megatooth sharks,' he added, highlighting what he found to be the report's key takeaway.
'That said, it is still useful to acknowledge that our understanding of the Meg is essentially limited to its ubiquitous teeth, a few vertebrae and a handful of scales. What I'd really love to see emerging from 'the foggy ruins of time' is a complete Meg skeleton… Let's hope that the fossil record will amaze us once again.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast
Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast

Yahoo

timean hour ago

  • Yahoo

Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast

Listen here on your chosen podcast platform. Cats develop dementia similarly to humans with Alzheimer's disease. Scientists hope their findings lead to new treatments for both humans and our feline friends. For more, we spoke to the lead author, Dr Robert McGeachan, at the University of Edinburgh's Royal School of Veterinary Studies. A swarm of jellyfish forced the shutdown of France's largest nuclear power plant, Gravelines. But how unusual is this event? And, Reddit blocks the Internet Archive's Wayback Machine from archiving large portions of its site. Also in this episode: -How blowing through a conch shell could alleviate the symptoms of obstructive sleep apnoea -Lola Young urges Keir Starmer to block Rosebank oil and gas development projects -Natalie the Nerd builds a transparent GameBoy Colour

Implantica publishes Interim Report January - June 2025 (Q2)
Implantica publishes Interim Report January - June 2025 (Q2)

Yahoo

time2 hours ago

  • Yahoo

Implantica publishes Interim Report January - June 2025 (Q2)

VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care Positive NICE Guidance in the UK - UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy Significant events after the end of the period Landmark 5-Year Clinical Study Results - Two peer-reviewed articles were published in Surgical Endoscopy on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care Randomized Clinical Trial (RCT) Launch - First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes Spanish Market Expansion - Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023 First UK National Users Meeting - Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation Financial summary second quarter 2025 Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial. Adjusted gross margin amounted to 90% (91%). Operating loss (EBIT) decreased to TEUR 4,525 (5,869). Loss after tax decreased to TEUR 5,448 (6,431). Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09). Cash and short-term investments as at the end of the period of MEUR 56.3. First six months Net sales increased 2% to TEUR 1,178 (1,150). Adjusted gross margin amounted to 94% (91%). Operating loss (EBIT) decreased to TEUR 8,698 (12,956). Loss after tax decreased to TEUR 8,212 (9,903). Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14). Telephone conference Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: Dial-in Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference. For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-14 08:00 CEST. About Implantica: Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q2 2025_ENG Implantica publishes Interim Report Jan - Jun 2025 Q2 View original content:

Norgine completes acquisition of Theravia
Norgine completes acquisition of Theravia

Yahoo

time2 hours ago

  • Yahoo

Norgine completes acquisition of Theravia

PARIS, Aug. 14, 2025 /PRNewswire/ -- Norgine today announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for patients with rare and debilitating conditions. The closure of this acquisition marks a major step forward for Norgine to deliver on its ambition to bring life-changing medicines to patients with high unmet medical needs. With the transaction now complete, Norgine will begin a structured integration process to align operations, systems, and teams. "We are pleased about the successful closing of this acquisition as the addition of Theravia to our company further enhances our expertise in, and growing portfolio of rare disease medicines," said Janneke van der Kamp, Chief Executive Officer, Norgine. "This acquisition marks a critical step forward in our growth strategy, and with our strong focus on expanding the reach of products to patients in areas of high unmet medical need in Europe and ANZ, we are well positioned to ensure Theravia's medicines will reach more patients." As a result of the acquisition, Theravia has become a wholly owned subsidiary of Norgine. Notes About Norgine Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with over €550 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across our core markets of Western Europe, Australia and New Zealand. Norgine's integrated approach – strong commercial capabilities, as well as deep medical, regulatory and clinical expertise, in-house manufacturing, robust supply networks, and best-in-class enabling functions – ensures that Norgine can deliver high-quality, transformative medicines quickly and effectively to over 25 million patients annually. Norgine is a nimble, innovative, and high-performing company that has been transformed by a relentless focus on operational excellence. This focus will enable us to secure the legacy of more than a century of innovation and doing the right thing by our patients, as we push the boundaries and take strides into therapeutic innovation. NORGINE and the sail logo are trademarks of the Norgine group of companies. Logo: Media contact: Annabel Cowperacowper1@ View original content: SOURCE Norgine Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store